Cargando…

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients

Detalles Bibliográficos
Autores principales:	Yousef, S, Marvin, J, Steinbach, M, Langemo, A, Kovacsovics, T, Binder, M, Kröger, N, Luetkens, T, Atanackovic, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382668/ https://www.ncbi.nlm.nih.gov/pubmed/25747678 http://dx.doi.org/10.1038/bcj.2015.7

Ejemplares similares

Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4(+) and CD8(+) T-cell responses in multiple myeloma patients
por: Reinhard, H, et al.
Publicado: (2014)

Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma
por: Yousef, Sara, et al.
Publicado: (2015)

CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
por: Radhakrishnan, Sabarinath V., et al.
Publicado: (2020)

Bone Marrow Gouty Tophi With Plasma Cell Myeloma
por: Bang, Hae In, et al.
Publicado: (2020)

The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma
por: Giannakoulas, Nikolaos, et al.
Publicado: (2021)

Giant multinucleated plasma cells in relapsed plasma cell myeloma
por: Ghattas, Sylvia, et al.
Publicado: (2020)

Myeloma therapy: pursuing the plasma cell
por: Cavenagh, J
Publicado: (2010)

Extracellular crystals in plasma cell myeloma
por: Brown, Jacqueline T., et al.
Publicado: (2014)

Plasma Cell Myeloma Masquerading as Scleromyxedema
por: Victor, Varun, et al.
Publicado: (2019)

Immune Checkpoint Programmed Cell Death Protein-1 (PD-1) Expression on Bone Marrow T Cell Subsets in Patients With Plasma Cell Myeloma
por: Lee, Min Young, et al.
Publicado: (2021)

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
por: Bisht, Kamlesh, et al.
Publicado: (2023)

Phenotypic consensus markers for plasma cell myeloma
por: Hur, Mina
Publicado: (2012)

Towards Stratified Medicine in Plasma Cell Myeloma
por: Egan, Philip, et al.
Publicado: (2016)

Toothache as the initial symptom of plasma cell myeloma
por: Wehrhahn, Tobias, et al.
Publicado: (2018)

Plasmablastic myeloma progressed to plasma cell leukaemia
por: Xu, Ke, et al.
Publicado: (2021)

Multifocal Extramedullary Plasma Cell Myeloma of the Colon
por: Karime, Christian, et al.
Publicado: (2023)

Artificial Intelligence in Plasma Cell Myeloma: Neural Networks and Support Vector Machines in the Classification of Plasma Cell Myeloma Data at Diagnosis
por: Yenamandra, Ashwini K., et al.
Publicado: (2021)

Under one roof: The bone marrow survival niche for multiple myeloma and normal plasma cells
por: Nair, Jayakumar R., et al.
Publicado: (2012)

DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment
por: Hewett, Duncan R., et al.
Publicado: (2017)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Longitudinal Analysis of Tetanus- and Influenza-Specific IgG Antibodies in Myeloma Patients
por: Kobold, Sebastian, et al.
Publicado: (2012)

Patients with Multiple Myeloma Develop SOX2-Specific Autoantibodies after Allogeneic Stem Cell Transplantation
por: Kobold, Sebastian, et al.
Publicado: (2011)

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
por: Sponaas, Anne-Marit, et al.
Publicado: (2015)

The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma
por: Braga, Walter M. T., et al.
Publicado: (2012)

PB2077: COMPARISON OF PLASMA CELL PERCENTAGE BY BONE MARROW ASPIRATE MORPHOLOGY AND CD138-STAINED BONE MARROW BIOPSY IN SMOLDERING MYELOMA TO PREDICT TRANSFORMATION TO SYMPTOMATIC MYELOMA
por: Cashman, Helen, et al.
Publicado: (2023)

Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation
por: Templin, Julia, et al.
Publicado: (2017)

Plasmablastic plasma cell myeloma mimicking plasmablastic lymphoma
por: Choi, Qute, et al.
Publicado: (2010)

Plasma Cell Myeloma Initially Presenting as Lung Cancer
por: Cho, Sun Young, et al.
Publicado: (2013)

Anaplastic plasma cell myeloma — A morphological dilemma
por: Raman Ramalingam, Thulasi, et al.
Publicado: (2022)

Flower-Like Plasma Cell Nuclei in Multiple Myeloma
por: Sall, Abibatou, et al.
Publicado: (2021)

Simultaneous presentation of plasma cell myeloma and hairy cell leukemia
por: Carulli, Giovanni, et al.
Publicado: (2019)

In vitro osteolytic activity of human myeloma plasma cells and the clinical evaluation of myeloma osteoclastic bone lesions.
por: Rossi, J. F., et al.
Publicado: (1984)

Prediction Model for Cereblon Expression in Bone Marrow Plasma Cells Based on Blood Markers in Multiple Myeloma Patients
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells
por: Stefka, A T, et al.
Publicado: (2016)

PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model
por: Lee, Byung-Hyun, et al.
Publicado: (2020)

THE FORMATION OF MYELOMA PROTEIN BY A MOUSE PLASMA CELL TUMOR
por: Nathans, Daniel, et al.
Publicado: (1958)

Plasma cell myeloma infiltrating the dental pulp: An interesting finding
por: George, Sanjith, et al.
Publicado: (2013)

Disseminated plasma cell myeloma presenting as massive pleural effusion
por: Babu, Kanahasubramanian Anand, et al.
Publicado: (2015)

Plasma Cell Sarcoma Complicating a Case of Multiple Myeloma
por: Sejeny, Saud A., et al.
Publicado: (1976)

Ascites in the Course of Plasma Cell Myeloma Complicated by AL Amyloidosis
por: Debski, Jakub, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l6r909hv59daegsep0487fdj6q